GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » WuXi XDC Cayman Inc (FRA:L74) » Definitions » COGS-to-Revenue

WuXi XDC Cayman (FRA:L74) COGS-to-Revenue : 0.78 (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is WuXi XDC Cayman COGS-to-Revenue?

WuXi XDC Cayman's Cost of Goods Sold for the three months ended in Jun. 2023 was €50.9 Mil. Its Revenue for the three months ended in Jun. 2023 was €65.2 Mil.

WuXi XDC Cayman's COGS to Revenue for the three months ended in Jun. 2023 was 0.78.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. WuXi XDC Cayman's Gross Margin % for the three months ended in Jun. 2023 was 21.95%.


WuXi XDC Cayman COGS-to-Revenue Historical Data

The historical data trend for WuXi XDC Cayman's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi XDC Cayman COGS-to-Revenue Chart

WuXi XDC Cayman Annual Data
Trend Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
0.92 0.64 0.74 0.74

WuXi XDC Cayman Quarterly Data
Dec20 Dec21 Mar22 Jun22 Dec22 Mar23 Jun23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial 0.72 - 0.76 0.78 -

WuXi XDC Cayman COGS-to-Revenue Calculation

WuXi XDC Cayman's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=200.897 / 272.76
=0.74

WuXi XDC Cayman's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=50.89 / 65.2
=0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


WuXi XDC Cayman  (FRA:L74) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

WuXi XDC Cayman's Gross Margin % for the three months ended in Jun. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 50.89 / 65.2
=21.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


WuXi XDC Cayman COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of WuXi XDC Cayman's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


WuXi XDC Cayman (FRA:L74) Business Description

Comparable Companies
Traded in Other Exchanges
Address
No. 11 Xinhui Ring Road, Xinwu, Jiangsu, Wuxi, CHN
Website
WuXi XDC Cayman Inc is a leading CRDMO focused on the global ADC and broader bioconjugate market and the only one dedicated to providing integrated and end-to-end services. Leveraging expertise in both biologics and small molecules, It offers interdisciplinary and comprehensive services, covering bioconjugate discovery, research, development and manufacturing. The company provides these services from proximately located, state-of-the-art laboratories and manufacturing facilities, leading to the significant reduction of development timeline and costs. As a fully integrated one-stop bioconjugate discovery, development and manufacturing platform, its mission is to continuously enhance its platform, and propel and transform the development of the bioconjugate industry.

WuXi XDC Cayman (FRA:L74) Headlines

No Headlines